Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Eli Lilly And Co (LLY) Price & Performance

Bitwise Crypto Industry Innovators ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Bitwise Crypto Industry Innovators ETF vs Eli Lilly And Co — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $23.58, while Eli Lilly And Co trades at $1,153.5 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while Bitwise Crypto Industry Innovators ETF pays none. Which is the better fit depends on your goals.

BITQLLY
Sector
Crypto-linkedHealth
52-Week High
$30.43$1.24K
52-Week Low
$16.74$625.65
Market Cap
$1.03T
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitwise Crypto Industry Innovators ETF

BITQ trades at $23.18, down 3.13% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators show neutral conditions. Support levels cluster around $23-24 while resistance sits at $25-26. Recent news highlights investor rotation away from crypto-related ETFs as Bitcoin prices decline, creating headwinds for BITQ's performance.

The outlook remains cautious given the bearish technical setup and sector-specific challenges. Investment opportunity exists for contrarian investors betting on crypto market recovery, but risks include continued ETF outflows and regulatory uncertainty. The stock's performance remains tightly correlated with broader cryptocurrency sentiment rather than standalone fundamentals.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitwise Crypto Industry Innovators ETF

BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.

Read more on BITQ

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY